Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanomaChiao‐En Wu, John Lunec|British Journal of Cancer|2017Cited by 63
ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous MelanomaChiao‐En Wu, John Lunec|Cancers|2018Cited by 39
TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic responseChiao‐En Wu, John Lunec|Cancer Cell International|2019Cited by 11